Triple negative breast cancer: Outcome correlation with immunohistochemical detection of basal markers

American Journal of Surgical Pathology

Volumn 34, Issue 7, 2010, Pages 956-964

  Thike, Aye Aye ^a   Iqbal, Jabed ^a   Cheok, Poh Yian ^a   Chong, Angela Phek Yoon ^a   Tse, Gary Man Kit ^b   Tan, Benita ^a   Tan, Patrick ^c   Wong, Nan Soon ^d   Tan, Puay Hoon ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

basal like; CD117; CK17; immunohistochemistry; survival; triple negative

Indexed keywords

ACTIN; BIOLOGICAL MARKER; CYTOKERATIN 17; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; LYMPH NODE; MASTECTOMY; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PHENOTYPE; SINGAPORE; SMOOTH MUSCLE;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KERATIN-17; LYMPH NODES; MASTECTOMY; MIDDLE AGED; MUSCLE, SMOOTH; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-KIT; SINGAPORE;

EID: 77954216525     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181e02f45     Document Type: Article

References (39)

1. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
2. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.
3. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
4. Chui X, Egami H, Yamashita J, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer. 1996;73:1233-1236.
5. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
6. Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115: 423-428.
7. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomer-uloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830-835.
8. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R4.
9. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22:207-219.
10. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol. 2009;20:1913-1927.
11. Gusterson BA, Ross DT, Heath VJ, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005;7:143-148.
12. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652-5657.
13. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN. Individualiza-tion of neoadjuvant therapy for breast cancer according to molecular tumor characteristics. Nat Clin Pract Oncol. 2005;2:598-599.
14. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30:1097-1104.
15. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279: 577-580. (Pubitemid 28067289)
16. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25:2127-2132.
17. Ivanov O, Chen F, Wiley EL, et al. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;111:411-417.
18. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009;15:454-460.
19. Kilburn LS. "Triple negative" breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol). 2008;20: 35-39.
20. Laakso M, Tanner M, Nilsson J, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res. 2006;12:4185-4191.
21. Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638-2645.
22. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19:264-271.
23. Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol). 2008;20:40-45.
24. Natali PG, Nicotra MR, Sures I, et al. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer. 1992;52: 713-717.
25. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
26. Pintens S, Neven P, Drijkoningen M, et al. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol. 2009;62:624-628.
27. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009;41:40-47.
28. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
29. Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 2007;9:404. (author reply 405).
30. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52:108-118.
31. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12: 1533-1539.
32. Seewaldt VL, Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med. 2007;356:e12.
33. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
34. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
35. Thike AA, Chng MJ, Fook-Chong S, et al. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology. 2001;33:21-25.
36. Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23:123-133.
37. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohisto-chemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.
38. Tommiska J, Bartkova J, Heinonen M, et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27:2501-2506.
39. Viale G, Rotmensz N, Maisonneuve P, et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116:317-328.